Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
REGULATORY
MHLW Presents Draft Optimal Use Guidelines for Keytruda: Chuikyo
The Ministry of Health, Labor and Welfare (MHLW) on January 25 presented a draft of “optimal use promotion guidelines” for anti-PD-1 antibody Keytruda (pembrolizumab) for the treatment of non-small cell lung cancer (NSCLC). The draft guidelines, tendered to the Central…
To read the full story
Related Article
- MHLW Lays Out Chuikyo Discussion Timeline for Drug Pricing Overhaul
January 26, 2017
- Industry Wants Simplified Rule, Limited Application for Foreign Price Adjustment: Chuikyo
January 26, 2017
- Chuikyo on Alert for Trump’s Possible Pressure on Drug Front
January 26, 2017
- (Update) Chuikyo Agrees to Shed US Price from Foreign Price Adjustment Rule
January 25, 2017
- PD-L1 Expression Testing Won’t Be a Must for Opdivo, but Clarification Needed: Chuikyo
December 15, 2016
REGULATORY
- Nakai Tapped as MHLW’s Top Pharmacy Officer; Ohara to Steer Drug Pricing Reform
August 7, 2026
- Sarclisa SC, Joenja, Kineret, and 7 More Drugs Bound for NHI Listing
August 6, 2026
- Tepezza Price Cut Set at 5.5% under Japan’s CEA Scheme
August 6, 2026
- Dupixent Faces Fourth Re-Pricing under Japan’s SPA-SSS
August 6, 2026
- Chuikyo Clears NHI Listing for Oncolys’ Telomelysin
August 6, 2026
Japan’s pharmaceutical policy appears to be entering a new phase. The government’s newly approved honebuto policy and growth strategy both…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…